Navigation Links
Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine
Date:6/19/2013

ites internationally, and 86 percent of patients had intermediate or high-risk MCL. Study participants received a 560mg daily oral dose of ibrutinib monotherapy and were treated into two cohorts based on prior exposure to bortezomib – either no prior bortezomib (n=63) or prior bortezomib (n=48). Overall, patients had received a median of three prior therapies.

About Mantle Cell Lymphoma
MCL, a B-cell malignancy, is an aggressive type of B-cell non-Hodgkin lymphoma (NHL) that usually occurs in older adults. The disease typically begins in the lymph nodes but can spread to other tissues, such as bone marrow and liver. Ibrutinib targets the B-cell receptor pathway an important pathway in malignant B-cell growth and proliferation. In the United States there are approximately 5,000 new cases of MCL each year.

About Ibrutinib
Ibrutinib was designed to specifically target and selectively inhibit an enzyme called Bruton tyrosine kinase (BTK). BTK is a key mediator of at least three critical B-cell pro-survival mechanisms occurring in parallel —regulation of apoptosis, cell adhesion, and cell migration and homing.

The effectiveness of ibrutinib alone or in combination with other treatments is being studied in several B-cell malignancies, including chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, Waldenstrom's macroglobulinemia and multiple myeloma. To date six Phase 3 trials have been initiated with ibrutinib and a total of 30 trials are currently registered on www.clinicaltrials.gov. Janssen Biotech, Inc. and Pharmacyclics entered a collaboration and license agreement in December 2011 to co-develop and co-commercialize ibrutinib.

About Pharmacyclics
Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commerciali
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine
2. Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
3. Ibrutinib Phase 2 Data: Analyses Show Efficacy with Ibrutinib Monotherapy in Patients with Relapsed or Refractory Mantle Cell or Diffuse Large B-cell Lymphoma
4. Ibrutinib Expanded Access Program Open to Eligible U.S. Patients with Relapsed or Refractory Mantle Cell Lymphoma
5. Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor
6. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
7. Ibrutinib Receives Two Oncology Breakthrough Therapy Designations from U.S. Food and Drug Administration
8. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
9. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
10. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
11. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014 Consolidated Net Profit ... Business Highlights   , India Business grew by ... 9.33% to Rs. 4,886.70 Mn Rest of World (ROW) ... Formulations Business grew by 34.53% to Rs. 977.26 Mn ... Glenmark Pharmaceuticals Limited, the research-led global integrated ...
(Date:7/24/2014)... Tenn. , July 24, 2014  In any ... one in 25 patients has at least one hospital-acquired ... Prevention. What,s more, many of these infections prove fatal. ... causing an alarming number of patient deaths per year, ... industry conversation. Consequently, a stronger emphasis ...
(Date:7/24/2014)... 24, 2014 /PRNewswire-iReach/ -- Delivery of the Report ... placed. Photo - http://photos.prnewswire.com/prnh/20140723/129707 ... in-depth market survey on Global and Chinese Hemodialysis ... information of Hemodialysis Machine including its classification, application ... and China,s top manufacturers of Hemodialysis Machine listing ...
Breaking Medicine Technology:Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 2Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 3Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 4Employees, Equipment and the Environment: Top Infection Prevention Focuses in Hospitals 2Employees, Equipment and the Environment: Top Infection Prevention Focuses in Hospitals 3Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 2Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 3Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 4Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 5
... Simcere Pharmaceutical Group (NYSE: SCR ), a ... marketing of branded generic and proprietary pharmaceuticals in China, ... results for the first quarter ended March 31, 2011 ... in the United States. Simcere,s management will host an ...
... 25, 2011 Leading events organiser UBM Live ... its CPhI, ICSE, P-MEC and BioPh Japan events in Tokyo ... the events have now been rescheduled and will be held ...  The Japanese business community is intent on picking itself up ...
Cached Medicine Technology:Simcere Pharmaceutical Group to Announce First Quarter 2011 Financial Results on Tuesday, May 10, 2011 2Boost For Japanese Pharma Market as UBM Announces Rescheduled Japan Pharma and Bio Events 2Boost For Japanese Pharma Market as UBM Announces Rescheduled Japan Pharma and Bio Events 3
(Date:7/25/2014)... July 25, 2014 Mahendra Trivedi and ... Online Workshop ‘Consciousness is Power’ on Saturday, July 26, ... to attend this life transforming event as they will ... higher level. Few days are left for the commencement ... Trivedi and Trivedi Masters™ Dahryn Trivedi (his wife) and ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 ... review recently updated by Vkool.com, this is ... how to treat some common types of ... and internal hemorrhoids ,     Young children ... with hemorrhoids ,     Very large hemorrhoids ...
(Date:7/25/2014)... 25, 2014 According to the ... updated by Vkool.com, this is a comprehensive guide ... natural and safe remedies for liver cirrhosis ... including:,     Chapter 1: Liver Cirrhosis ... 2: Learn About Liver Basics ,     Chapter ...
(Date:7/24/2014)... (PRWEB) July 25, 2014 Journal ... be affected by the width of the alveolar ridge—an ... the implant. A variety of methods exist, each with ... augmentation techniques. The ridge-split graft is highlighted as a ... Journal of Oral Implantology offers a comparison of ...
(Date:7/24/2014)... [Brown University] The U.S. Preventive Services Task ... for people at high risk for cancer, but ... patients will have positive results on the screening ... testing. Many policymakers have expressed concern that this ... needlessly upset. A new study of National Lung ...
Breaking Medicine News(10 mins):Health News:Mahendra Trivedi to Host an Online Workshop ‘Consciousness is Power’ 2Health News:Mahendra Trivedi to Host an Online Workshop ‘Consciousness is Power’ 3Health News:Hemorrhoid No More Pdf Review Exposes Jessica Wright's Guide For Treating Hemorrhoids – Vkool.com 2Health News:Hemorrhoid No More Pdf Review Exposes Jessica Wright's Guide For Treating Hemorrhoids – Vkool.com 3Health News:Liver Cirrhosis Bible & Ezra Protocol Review Exposes Debra Elkin's Liver Cirrhosis Treatment Guide – Vkool - Better Information, Better Lives 2Health News:Liver Cirrhosis Bible & Ezra Protocol Review Exposes Debra Elkin's Liver Cirrhosis Treatment Guide – Vkool - Better Information, Better Lives 3Health News:A Comparison of Graft Techniques for the Alveolar Ridge Prior to Oral Implant 2Health News:A Comparison of Graft Techniques for the Alveolar Ridge Prior to Oral Implant 3Health News:Informed consent: False positives not a worry in lung cancer study 2Health News:Informed consent: False positives not a worry in lung cancer study 3
... in Awareness and Treatment of Mental Disorders Will Drive China,s ... According to a New Report From Decision Resources , ... Decision Resources, one of the world,s leading research and advisory ... views on mental disorders are improving but challenges remain. According ...
... Dec. 11 HairRemovalForum.com, a leading provider of hair removal ... new features to make it easier for guests to locate ... , In recent weeks, Hair ... allowing guests to research service providers in a number of ...
... there are no easy discounts because of where you live or ... money is totally out of your control.  Here are a few ... -  Do the Math: While a plan with a lower ... generally come with either higher co-pays (the part you pay out-of-pocket ...
... Launch extends range of treatment options and empowers wound care professionals ... the patient, the wound and the care setting. , ... Advanced Wound Management Division of Smith & Nephew (LSE: SN; NYSE: ... a foam dressing kit for Negative Pressure Wound Therapy (NPWT). ...
... Greater Access to Renal Function and MetLyte 8 Panels ... UNION CITY, Calif., Dec. 11 Abaxis, Inc. ... manufacturing point-of-care blood analysis systems, today announced that the ... status under CLIA regulations for two additional analytes, Creatine ...
... for commissioned insurance sales agents in Canada are on the rise ... ... Despite recent reports by Statistics Canada that unemployment is growing and ... of supplemental insurance, reports job opportunities for commissioned insurance sales agents ...
Cached Medicine News:Health News:China's Views on Mental Disorders Improving but Challenges Remain 2Health News:China's Views on Mental Disorders Improving but Challenges Remain 3Health News:Hair Removal Forum Unveils New 'Doctor Finder' Interface 2Health News:How to Save Money on Health Insurance 2Health News:Introducing the Smith & Nephew Foam Dressing Kit 2Health News:Introducing the Smith & Nephew Foam Dressing Kit 3Health News:Introducing the Smith & Nephew Foam Dressing Kit 4Health News:Abaxis Point-of-Care Test Panels Gain FDA CLIA-Waived Status 2Health News:Abaxis Point-of-Care Test Panels Gain FDA CLIA-Waived Status 3Health News:Abaxis Point-of-Care Test Panels Gain FDA CLIA-Waived Status 4Health News:Insurance Job Opportunities Rise in Canada in Spite of Challenging Economy 2Health News:Insurance Job Opportunities Rise in Canada in Spite of Challenging Economy 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: